PaxMedica, Inc. Common Stock (PXMD)
USD 0.0
(0.0%)
USD 0.0
(0.0%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | -16.14 Million USD | 2.2% |
| 2022 | -10.6 Million USD | -135.01% |
| 2021 | -7.19 Million USD | -25.0% |
| 2020 | -5.61 Million USD | -838.74% |
| 2019 | -598.6 Thousand USD | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q1 | -3.69 Million USD | 15.8% |
| 2024 Q2 | -2.99 Million USD | 18.83% |
| 2023 Q2 | -3.48 Million USD | 8.19% |
| 2023 FY | - USD | 2.2% |
| 2023 Q1 | -3.79 Million USD | 25.03% |
| 2023 Q3 | -4.69 Million USD | -34.69% |
| 2023 Q4 | -4.38 Million USD | 6.49% |
| 2022 Q4 | -5.05 Million USD | 54.43% |
| 2022 Q3 | -11.1 Million USD | -50115.56% |
| 2022 Q2 | 22.19 Thousand USD | 105.99% |
| 2022 Q1 | -370.3 Thousand USD | -116.88% |
| 2022 FY | - USD | -135.01% |
| 2021 Q2 | -2.87 Million USD | 28.47% |
| 2021 Q1 | -4.02 Million USD | -84.79% |
| 2021 FY | - USD | -25.0% |
| 2021 Q4 | 2.19 Million USD | 194.5% |
| 2021 Q3 | -2.32 Million USD | 19.29% |
| 2020 Q4 | -2.17 Million USD | -32.58% |
| 2020 Q3 | -1.64 Million USD | -7.49% |
| 2020 Q2 | -1.52 Million USD | -454.8% |
| 2020 FY | - USD | -838.74% |
| 2020 Q1 | -275.22 Thousand USD | 0.0% |
| 2019 Q1 | -114.37 Thousand USD | 0.0% |
| 2019 Q2 | -137.89 Thousand USD | -20.56% |
| 2019 FY | - USD | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| America Great Health | -447.29 Thousand USD | -3509.559% |
| Ampio Pharmaceuticals, Inc. | - USD | Infinity% |
| Aridis Pharmaceuticals, Inc. | -29.5 Million USD | 45.281% |
| Biora Therapeutics, Inc. | -114.05 Million USD | 85.844% |
| Bio-Path Holdings, Inc. | -15.76 Million USD | -2.438% |
| Better Therapeutics, Inc. | -38.26 Million USD | 57.803% |
| Calithera Biosciences, Inc. | -38.26 Million USD | 57.807% |
| Comera Life Sciences Holdings, Inc. | -17.88 Million USD | 9.735% |
| Gene Biotherapeutics, Inc. | - USD | Infinity% |
| eFFECTOR Therapeutics, Inc. | -33.73 Million USD | 52.138% |
| Eloxx Pharmaceuticals, Inc. | -33.37 Million USD | 51.622% |
| Evelo Biosciences, Inc. | -106.34 Million USD | 84.818% |
| Evolutionary Genomics, Inc. | -913.47 Thousand USD | -1667.46% |
| Finch Therapeutics Group, Inc. | -32.48 Million USD | 50.295% |
| Galera Therapeutics, Inc. | -46.69 Million USD | 65.422% |
| Innovation1 Biotech Inc. | -5.68 Million USD | -184.06% |
| Kiromic BioPharma, Inc. | -16.3 Million USD | 0.957% |
| Molecular Templates, Inc. | 1.43 Million USD | 1229.04% |
| Navidea Biopharmaceuticals, Inc. | -13.87 Million USD | -16.361% |
| NexImmune, Inc. | -28.16 Million USD | 42.681% |
| Orgenesis Inc. | -60.71 Million USD | 73.409% |
| Panbela Therapeutics, Inc. | -51.29 Million USD | 68.524% |
| Point of Care Nano-Technology, Inc. | -73.41 Thousand USD | -21891.487% |
| Scopus BioPharma Inc. | -11.71 Million USD | -37.839% |
| Sorrento Therapeutics, Inc. | -539.92 Million USD | 97.01% |
| Statera Biopharma, Inc. | 38.93 Million USD | 141.467% |
| TRACON Pharmaceuticals, Inc. | -6.88 Million USD | -134.533% |
| Trevena, Inc. | -35.28 Million USD | 54.247% |
| Vaxxinity, Inc. | -56.05 Thousand USD | -28704.607% |
| Vaccinex, Inc. | -19.74 Million USD | 18.244% |
| Vicapsys Life Sciences, Inc. | -1.04 Million USD | -1442.083% |
| Viracta Therapeutics, Inc. | -46.86 Million USD | 65.547% |
| ZIVO Bioscience, Inc. | -7.26 Million USD | -122.294% |